从伊朗分离出各种血清型溶血曼海姆菌并制备出首个候选疫苗。
Isolation of the various serotypes of Mannheimia haemolytica and preparation of the first vaccine candidate in Iran.
机构信息
Immunology Department, Shiraz Branch, Agricultural Research, Razi Vaccine and Serum Research Institute, Education and Extension Organization (AREEO), Shiraz, Iran.
Microbiology Department, Shiraz Branch, Agricultural Research, Razi Vaccine and Serum Research Institute, Education and Extension Organization (AREEO), Shiraz, Iran.
出版信息
Mol Biol Rep. 2022 Nov;49(11):10367-10375. doi: 10.1007/s11033-022-07890-4. Epub 2022 Sep 12.
BACKGROUND
Mannheimia haemolytica is one of the main agents of domestic pneumonic mannheimiosis, but a proper vaccine has not been explored in IRAN.
METHODS AND RESULTS
362 lung and nasal samples from sick domestic animal were detected by culture and PCR methods. Totally, 71 M. haemolytica isolates were identified in three main serotypes (A1, A2, and A6). Serotypes A2 (38/71; 54%) and A1 (25/71; 39%) were the most frequently detected, whereas the A6 serotype was detected with a frequency of less than 1% (1/71; 1%) and 7 isolates remained unknown (7/71; 10%). Subsequently, M. haemolytica vaccinal strain was developed and then formalin-killed vaccine was prepared. It provided the best protection against mannheimiosis in sheep which was proved by indirect ELISA.
CONCLUSIONS
Our results suggest that the efficacy and safety of vaccine strain are remarkable and may serve as a new therapeutic target in mannheimiosis.
背景
溶血曼海姆菌是国内肺炎型曼海姆氏菌病的主要病原体之一，但在伊朗尚未探索出合适的疫苗。
方法和结果
通过培养和 PCR 方法检测了来自患病家畜的 362 个肺和鼻样本。总共从三个主要血清型（A1、A2 和 A6）中鉴定出 71 株溶血曼海姆菌分离株。血清型 A2（38/71；54%）和 A1（25/71；39%）是最常检测到的，而 A6 血清型的检出率低于 1%（1/71；1%），7 株分离株未知（7/71；10%）。随后，开发了溶血曼海姆菌疫苗株，然后制备了甲醛灭活疫苗。间接 ELISA 证明，该疫苗对绵羊的曼海姆氏菌病提供了最佳保护。
结论
我们的结果表明，疫苗株的疗效和安全性显著，可能成为曼海姆氏菌病的新治疗靶点。
Zotero 插件